Mylan Wants Investors' 'Copycat' EpiPen Claims Dismissed
Drugmaker Mylan NV on Monday urged a New York federal court to dismiss investors' amended allegations about alleged anti-competitive behavior involving its EpiPen epinephrine autoinjector, saying the bulk of the allegations...To view the full article, register now.
Already a subscriber? Click here to view full article